GET THE APP

From Stents to Gene Therapy: The Future of Coronary Interventions
Journal of Coronary Heart Diseases

Journal of Coronary Heart Diseases

ISSN: 2684-6020

Open Access

Brief Report - (2024) Volume 8, Issue 5

From Stents to Gene Therapy: The Future of Coronary Interventions

Morles Rafel*
*Correspondence: Morles Rafel, Department of Heart Health, University of Guadalara, Mexico, Email:
1Department of Heart Health, University of Guadalara, Mexico

Published: 31-Oct-2024 , DOI: 10.37421/2684-6020.2024.8.236

Introduction

Coronary interventions, particularly the use of Percutaneous Coronary Interventions (PCI) and stents, have revolutionized the treatment of Coronary Artery Disease (CAD) over the past few decades. PCI, commonly referred to as angioplasty, involves the insertion of a catheter to open blocked or narrowed coronary arteries, often accompanied by stent placement to maintain the arteryâ??s patency. This intervention has significantly reduced mortality and morbidity associated with CAD, providing a less invasive alternative to Coronary Artery Bypass Grafting (CABG). However, despite the successes of stent technology, challenges remain, including the risk of restenosis (re-narrowing of the artery) and stent thrombosis (formation of a blood clot). These limitations, along with the growing burden of CAD and an aging population, have spurred the search for next-generation treatments. Looking ahead, the future of coronary interventions is likely to involve more personalized and biologically sophisticated approaches, with advancements in drug-eluting stents, bioresorbable stents, and, potentially, gene therapy offering the promise of more effective and lasting solutions. The focus is shifting from merely unblocking arteries to addressing the underlying pathophysiology of CAD at a molecular and genetic level, which could radically change the landscape of coronary intervention. In this context, gene therapy and regenerative medicine are gaining attention as potential game-changers for the future of cardiovascular care. [1] The integration of gene therapy into coronary interventions represents a major leap forward in the treatment of CAD. While traditional stents and PCI have been effective in restoring blood flow, they do not address the underlying causes of atherosclerosis, such as plaque buildup, endothelial dysfunction, or smooth muscle cell proliferation. Gene therapy has the potential to modify the molecular pathways involved in CAD and promote the regeneration of damaged cardiovascular tissue. By delivering therapeutic genes directly to the heart or vascular system, gene therapy could help restore normal endothelial function, reduce inflammation, and even induce the growth of new blood vessels (angiogenesis) to bypass occluded arteries. This approach could provide long-term solutions for patients with CAD, particularly those with complex or inoperable lesions. Furthermore, advances in genetic editing technologies, such as CRISPR, are opening the door to more precise and targeted therapies. These innovations could not only improve the efficacy of current treatments but also reduce the risk of complications like restenosis and stent failure. As we move toward more personalized treatment options, the integration of gene therapy into routine coronary interventions holds great promise for transforming the way CAD is treated and managed in the future. [2]

Description

The evolution of coronary interventions has been driven by the need for more effective and safer treatments for CAD. Traditional stents, particularly bare-metal stents (BMS), revolutionized PCI by providing a means to mechanically hold open the artery after balloon angioplasty. However, BMS were often limited by high rates of restenosis, which occurred as the vessel narrowed again due to the body’s inflammatory response to the stent. The advent of drug-eluting stents (DES), which release medication directly into the artery to prevent cell growth and reduce restenosis rates, marked a significant advancement in coronary intervention. DES have since become the standard of care for most patients undergoing PCI, offering better long-term outcomes and lower rates of restenosis compared to BMS. Despite this success, complications such as stent thrombosis, late-stage restenosis, and the need for long-term dual antiplatelet therapy (DAPT) persist, raising questions about the durability and safety of current stent technologies. In response to these challenges, the development of bioresorbable stents (BRS) has emerged as a promising innovation. BRS are designed to gradually dissolve over time, potentially eliminating the need for permanent foreign material in the coronary artery. These stents are made from biodegradable materials that provide temporary structural support during the healing phase, reducing the risk of complications associated with long-term stent placement. Early clinical trials of bioresorbable stents have shown encouraging results, though further research is needed to determine their long-term effectiveness and safety [3].

Gene therapy is poised to address some of the fundamental challenges that current coronary interventions cannot resolve, particularly in relation to plaque formation and the repair of damaged heart tissue. One potential strategy involves the use of gene transfer to promote endothelial cell regeneration and restore normal blood vessel function. In CAD, endothelial dysfunction plays a key role in the progression of atherosclerosis, leading to the accumulation of plaque and narrowing of the arteries. By delivering genes that encode for endothelial growth factors or other proteins that can promote endothelial cell repair, it may be possible to halt or even reverse the process of atherosclerosis. Additionally, gene therapy could be used to enhance angiogenesis, the formation of new blood vessels, which could help bypass occluded arteries and improve blood supply to ischemic heart tissue. For patients with advanced CAD, where coronary artery bypass surgery or PCI may not be feasible, gene therapy could offer a life-saving alternative by promoting vascular regeneration at the site of the blockage. Recent preclinical studies have demonstrated the potential of gene therapies to promote the growth of new blood vessels and improve myocardial perfusion in animal models, with ongoing clinical trials exploring the safety and efficacy of these approaches in humans. Although gene therapy for CAD is still in the experimental stages, the possibility of applying this technology to clinical practice could be a transformative step forward in the treatment of coronary artery disease [4].

The future of coronary interventions may also involve the integration of stem cell-based therapies in addition to gene therapy. Stem cells, particularly mesenchymal stem cells (MSCs) and induced pluripotent stem cells (iPSCs), have shown promise in regenerative medicine by differentiating into various cell types, including endothelial cells, smooth muscle cells, and cardiomyocytes. When injected into the heart or coronary arteries, stem cells could potentially repair damaged tissue, promote vascular growth, and improve heart function in patients with severe CAD or heart failure. Stem cell therapies could also be used in combination with gene therapy to enhance tissue repair and regeneration, creating a synergistic effect that could improve the outcomes of coronary interventions. While the clinical application of stem cell therapies remains in the early stages, studies have demonstrated encouraging results in preclinical models, and several clinical trials are underway to assess the feasibility and safety of stem cell-based treatments for CAD. However, challenges remain in terms of cell sourcing, immune rejection, and ensuring the long-term viability of transplanted cells. As both stem cell and gene therapy research advances, the potential for personalized, regenerative therapies to complement or replace traditional stenting and PCI could offer a new frontier in the treatment of coronary artery disease [5].

Conclusion

The future of coronary interventions lies in integrating innovative technologies such as gene therapy and stem cell-based treatments alongside traditional approaches like stenting and PCI. While current interventions have significantly improved outcomes for patients with CAD, challenges such as restenosis, stent thrombosis, and limited long-term efficacy remain. Gene therapy has the potential to address the root causes of CAD by promoting endothelial regeneration, reducing inflammation, and stimulating angiogenesis, while stem cell therapies could offer the possibility of repairing damaged tissue and regenerating blood vessels. Furthermore, the development of bioresorbable stents represents a step forward in reducing the risks associated with long-term foreign material in the artery. Together, these advancements could lead to more personalized, targeted, and effective treatments for CAD, offering better long-term outcomes and improving quality of life for patients. However, while these technologies hold immense promise, significant challenges remain in terms of clinical translation, safety, and efficacy. Ongoing research, clinical trials, and technological advancements will be crucial in determining how these therapies can be integrated into routine clinical practice. As we look toward the future, the combination of traditional coronary interventions and emerging regenerative therapies may revolutionize the way CAD is treated, offering hope for more effective and lasting solutions to this widespread cardiovascular disease.

References

  1. Ionescu, Daniela and Simona Margarit. "In between opioid crisis and the need to treat pain, where do we stand?." J Crit Care Med (2022): 229-231.
  2. Google Scholar, Crossref, Indexed at

  3. Guadamuz, Jenny S., G. Caleb Alexander, Tanya Chaudhri and Rebecca Trotzky-Sirr,et al. "Availability and cost of naloxone nasal spray at pharmacies in Philadelphia, Pennsylvania, 2017." JAMA Netw. Open. (2019): e195388-e195388.
  4. Google Scholar, Crossref, Indexed at

arrow_upward arrow_upward